Ivan Ahel

• Illustrating the complexity of PARP-dependent pathways and highlighting underexplored hydrolases, regulators, and effectors with therapeutic potential

• Showcasing emerging early-stage discovery programs targeting alternative hydrolases as biomarkers and drug targets

• Encouraging broader exploration of DDR biology to avoid “PARP tunnel vision” and inspire innovation in next-generation DDR therapies